Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: HIV ribozyme gene therapy, Gene Shears Pty Ltd.

R de Feyter1, P Li

  • 1Gene Shears Pty Ltd, GPO Box 1600, Canberra, ACT 2601, Australia. rdefeyter@pican.pi.csiro.au

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary

Catalytic RNAs called ribozymes are being developed as therapies for HIV. Hammerhead ribozymes targeting HIV genes showed promise in protecting cells and are now in human safety trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of intravenous flavopiridol formulations.

PDA journal of pharmaceutical science and technology·2001
Same author

A secretin releasing peptide exists in dog pancreatic juice.

Life sciences·2001
Same author

Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149).

Journal of acquired immune deficiency syndromes (1999)·2000
Same author

Potentiation of nerve growth factor-action by picrosides I and II, natural iridoids, in PC12D cells.

European journal of pharmacology·2000
Same author

Pharmacokinetic study and determination of imperialine, the major bioactive component in antitussive Fritillaria cirrhosa, in rat by high-performance liquid chromatography coupled with evaporative light-scattering detector.

Analytical biochemistry·2000
Same author

Aberrant cell cycle progression contributes to the early-stage accelerated carcinogenesis in transgenic epidermis expressing the dominant negative TGFbetaRII.

Oncogene·2000

Area of Science:

  • Biochemistry
  • Molecular Biology
  • RNA Therapeutics

Background:

  • Ribozymes are catalytic RNA molecules with therapeutic potential.
  • Hammerhead ribozymes can be designed to target specific disease-related RNA sequences.
  • HIV infection poses a significant global health challenge.

Purpose of the Study:

  • To develop ribozyme-based therapeutics for HIV infection.
  • To target essential HIV genes, such as the tat gene and the Psi packaging sequence, using hammerhead ribozymes.
  • To evaluate the efficacy of ribozymes in protecting cells from viral infection.

Main Methods:

  • Engineering hammerhead ribozymes to target HIV RNA.
  • Expressing ribozyme constructs in hematopoietic cells in culture.
  • Conducting Phase I clinical trials to assess safety and feasibility.

Main Results:

  • Ribozymes successfully protected hematopoietic cells against HIV infection in vitro.
  • The anti-tat ribozyme demonstrated potential therapeutic activity.
  • Phase I clinical trials for the anti-tat ribozyme are currently underway.

Conclusions:

  • Hammerhead ribozyme technology shows promise as a novel therapeutic strategy against HIV.
  • Further clinical evaluation is necessary to establish the safety and efficacy of ribozyme therapy in humans.
  • This approach offers a potential new avenue for HIV treatment.

Related Experiment Videos